Answer
It targets the endothelin pathway, which is not directly blocked by most established antihypertensive medicines. Its UK licence is specifically as add-on treatment for resistant hypertension.
Sources for this answer
- JERAYGO 12.5 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 1
- UK Government